New Companies
Filter News
Found 3,826 articles
-
The Third Rock Ventures-backed startup has a pipeline of Treg therapeutics aimed at multiple sclerosis, type 1 diabetes and inclusion body myositis.
-
Money on the Move: June 16 – 22
6/23/2021
Life sciences advances continue to be an exciting opportunity for investors. Here's a glance at the companies attracting fresh funding the past week. -
Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells to Treat Serious Autoimmune and Inflammatory Diseases
6/23/2021
Third Rock Ventures today announced the launch of Abata Therapeutics.
-
Founded in 2014, Insilico focuses on using artificial intelligence for drug discovery and development.
-
The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.
-
Money on the Move: June 9-15
6/16/2021
Each week more money pours into the biopharma world. Here's a peek at who's getting a taste of fresh funds this week. -
The new division would benefit from Hahn's experience and help steer the company's Preemptive Medicine and Health Security initiative.
-
Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.
-
Valo Health is the latest company to go public through a merger with a special purpose acquisition company. It will merge with Khosla Ventures Acquisition Co. and begin to trade on the Nasdaq.
-
Unicorn Hunters is a new Internet reality show where startup companies can pitch a group of well-known panelists dubbed the “Circle of Money” which allows for a kind of crowdsourced funding appeal.
-
Organon’s focus will center on reproductive health, health conditions, and issues unique to women and diseases that disproportionately impact women.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Foresight Diagnostics completes Series A financing to accelerate its industry-leading minimal residual disease (MRD) technology
6/2/2021
Foresight Diagnostics today announced the close of its $12.5M Series A financing led by Civilization Ventures and Bluebird Ventures, with participation by Pear Ventures, to commercialize the industry’s most sensitive minimal residual disease (MRD) detection assay.
-
Engine is ready to drive its lead program into clinical trials by 2023 while Giiant’s preclinical program will target moderate-to-severe ulcerative colitis.
-
Money on the Move: May 19-25
5/26/2021
Drug development requires solid funding. Here's who's standing on higher ground this week with fresh investment dollars. -
Thanks to a recent joint venture, there is a new company taking on cancer and autoimmune diseases.
-
Seegrid Announces ‘Blue Labs’ Research and Development Group
5/25/2021
Seegrid Corporation, the leader in autonomous mobile robots (AMRs) for material handling, announced the formation of Blue Labs, a research and development group committed to furthering the company’s strong technical advantage.
-
Nevakar Inc. Announces Formation Of Nevakar Injectables
5/25/2021
Nevakar Inc., a privately held biopharmaceutical company, announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care, acute pain management, long acting injectables and hospital infections.
-
Vyluma Inc. Launches With Robust Opthalmic Portfolio, Leading With A Pharmaceutical Treatment In Phase III For Myopia
5/25/2021
Vyluma Inc. announces its establishment as a wholly owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions.
-
Nevakar Announces Formation Of Ophthalmic Company, Vyluma
5/25/2021
Nevakar Inc., a privately held biopharmaceutical company, announces the establishment of Vyluma Inc., a newly formed company with a focus on the development and commercialization of therapies to treat ophthalmic diseases.